Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586426 · ClinicalTrials.gov registry record · Phase 1
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT04586426: Active Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.
NCT04586426 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 228 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04586426, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).
Primary Outcome
The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Talquetamab
Study Locations (20)
Other
- St Vincents Hospital Melbourne - Fitzroy
- Royal Perth Hospital - Perth
- Hadassah Medical Center - Jerusalem
New York
- Mount Sinai Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Atrium Health - Charlotte
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center - Winston-Salem
Alberta
- Arthur J E Child Comprehensive Cancer Centre - Calgary
- Alberta Health Services - Edmonton
Alabama
- University of Alabama at Birmingham, Comprehensive Cancer Center - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- Colorado Blood Cancer Institute - Denver
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2026-10-27 |
| Phase | Phase 1 |
What the registry record for NCT04586426 still lists
NCT04586426 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab is the first listed.
NCT04586426 names 20 study sites across 15 states, led by Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04586426 about?
NCT04586426 is a clinical study titled "A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with ...
What is the current status of trial NCT04586426?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 228 participants. The study started on 2020-12-15. Estimated completion is 2026-10-27.
What conditions does trial NCT04586426 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04586426?
The interventions under investigation include: Teclistamab (DRUG), Talquetamab (DRUG).
Who is sponsoring clinical trial NCT04586426?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04586426 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Colorado, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04586426's enrollment target sits among peer trials
228 97th of 438 higher than 342 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI